Verve Therapeutics, Inc. Stock Price, News & Analysis

Verve Therapeutics recently received the Paul Dudley White International Scholar Award from the American Heart Association for the highest-ranked abstract from the U.S. at Scientific Sessions 2022. This recognition is based on preclinical results for VERVE-101, a gene editing medicine targeting PCSK9 to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). The study in non-human primates showed significant reductions in both PCSK9 protein and LDL cholesterol levels, with no germline transmission. The data will be presented at the AHA meeting from November 5-7, 2022.

Verve Therapeutics, a biotechnology company focused on cardiovascular disease, has announced its participation in several investor conferences. Key events include the Guggenheim 2022 Nantucket Therapeutics Conference on September 28, the Jefferies Cell and Genetic Medicine Summit on September 29, the Chardan 6th Annual Genetic Medicine Conference on October 4, the BMO Virtual Biopharma Spotlight Series on October 6, and the Truist Securities Genetic Medicine Summit on October 20.

Live webcasts will be available on the company’s investor website for 60 days post-event.

Verve Therapeutics has received clearance for its Clinical Trial Authorization (CTA) application from the UK Medicines and Healthcare products Regulatory Agency for VERVE-101, aimed at treating heterozygous familial hypercholesterolemia (HeFH). This achievement marks the second regulatory clearance for VERVE-101, which is currently in the heart-1 clinical trial in New Zealand and set to begin patient enrollment in the UK. The trial aims to assess the safety and tolerability of VERVE-101 and gather interim clinical data in 2023, showcasing Verve's commitment to innovating cardiovascular disease care.

Verve Therapeutics has announced new preclinical data for its gene editing candidate, VERVE-201, aimed at treating homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. This candidate targets the ANGPTL3 gene in the liver, significantly impacting cholesterol metabolism. Promising results showed potent, on-target editing in human liver cells and substantial reductions in ANGPTL3 protein levels in non-human primates. The company plans to present this data at the European Society of Cardiology 2022 Congress on August 29, 2022, and anticipates moving towards clinical trials in 2024.

Verve Therapeutics reported significant advancements, including over $300 million added to its balance sheet, supporting operations well into the second half of 2025.

VERVE-101, aimed at treating heterozygous familial hypercholesterolemia, initiated patient dosing with interim clinical data expected in 2023. Regulatory clearances in the UK and US are anticipated soon.

The company also nominated VERVE-201 for ANGPTL3 treatment, with upcoming data presentations and IND-enabling studies in the pipeline. Additionally, new board members were appointed to bolster strategic growth.

Verve Therapeutics (Nasdaq: VERV) has successfully closed an upsized public offering of 9,583,334 shares at $27.00 per share, generating gross proceeds of $258.8 million. The offering's total includes 1,250,000 shares from underwriters' exercised options. Shares were sold under a shelf registration statement approved by the SEC. This financing aims to advance Verve's gene editing therapies targeting cardiovascular disease.

Verve Therapeutics, Inc. (Nasdaq: VERV) announced an upsized underwritten public offering of 8,333,334 shares of its common stock priced at $27.00 each, aiming for approximately $225 million in gross proceeds. The offering, fully underwritten, is set to close on July 25, 2022, subject to customary conditions. Additionally, underwriters may purchase up to 1,250,000 additional shares. Verve plans to utilize the funds to advance its gene editing therapies targeting cardiovascular disease, particularly focusing on PCSK9 and ANGPTL3.

Verve Therapeutics (Nasdaq: VERV) has initiated an underwritten public offering of $200 million in common stock. The offering includes an option for underwriters to purchase up to an additional 15% of the shares, subject to market conditions. The company is leveraging a shelf registration statement effective as of July 12, 2022. This offering aims to support Verve's innovative approach to addressing cardiovascular disease through single-course gene editing, targeting genes like PCSK9 and ANGPTL3.

Verve Therapeutics has announced a collaboration with Vertex Pharmaceuticals, securing a $60 million upfront payment, which includes a $35 million equity investment. The partnership aims to develop an in vivo gene editing program targeting a specific liver disease over four years. Vertex will finance the research, while retaining rights to future development and commercialization. Verve could also earn up to $406 million in milestone payments and royalties on potential net sales. This collaboration marks a pivotal step in Verve's ongoing efforts to innovate gene editing therapies for cardiovascular diseases.